Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia

The PI3K/AKT and mTOR signaling pathways are activated in acute myeloid leukemia, including in the more immature leukemic populations. Constitutive PI3K activation is detectable in 50% of acute myeloid leukemia samples whereas mTORC1 is activated in all cases of this disease. In leukemic cells, the PI3K activity relates to the expression of the p110δ isoform of class IA PI3K. Constitutive PI3K activation is the result of autocrine IGF-1/IGF-1R signaling in 70% of acute myeloid leukemia samples but specific inhibition of this pathway does not induce apoptosis. Specific inhibition of PI3K/AKT or mTORC1 alone in vitro has anti-leukemic effects which are essentially exerted via the suppression of proliferation. However, as mTORC1 activation is independent of PI3K/AKT in acute myeloid leukemia, dual PI3K and mTOR inhibitors may induce apoptosis in blast cells. Moreover, mTORC1 inhibition using sirolimus overactivates PI3K/AKT via the upregulation of IRS2 expression and by favoring IGF-1/IGF-1R autocrine signaling. Recent data also indicate that mTORC1 does not control protein translation in acute myeloid leukemia. These results open the way for the design of direct inhibitors of protein synthesis as novel acute myeloid leukemia therapies and also for the development of second generation mTOR inhibitors (the TORKinhibs).

[1]  J. Griffin,et al.  FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins , 2004, Oncogene.

[2]  D. Gilliland,et al.  Molecular genetics of human leukemias: new insights into therapy. , 2002, Seminars in hematology.

[3]  Srinivas Annavarapu,et al.  Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. , 2005, Blood.

[4]  P. Finan,et al.  Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. , 2004, Nature.

[5]  M. Waterfield,et al.  Signalling through phosphoinositide 3-kinases: the lipids take centre stage. , 1999, Current opinion in cell biology.

[6]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[7]  Stephen L. Abrams,et al.  Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia , 2008, Leukemia.

[8]  J. Tamburini,et al.  Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. , 2006, Haematologica.

[9]  L. Cuzin,et al.  The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia , 2009, Leukemia.

[10]  Steven P. Gygi,et al.  mTOR and S6K1 Mediate Assembly of the Translation Preinitiation Complex through Dynamic Protein Interchange and Ordered Phosphorylation Events , 2005, Cell.

[11]  K. Inoki,et al.  TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling , 2002, Nature Cell Biology.

[12]  J. Carpten,et al.  PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation , 2008, British journal of haematology.

[13]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[14]  G. Powis,et al.  Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. , 2004, Experimental hematology.

[15]  J. McCubrey,et al.  Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells , 2008, Leukemia.

[16]  J. Tamburini,et al.  Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. , 2008, Blood.

[17]  D. Mukhopadhyay,et al.  Insulin receptor substrate-2 mediated insulin-like growth factor-I receptor overexpression in pancreatic adenocarcinoma through protein kinase Cdelta. , 2009, Cancer research.

[18]  M. Weber,et al.  Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. , 2002, Leukemia.

[19]  A. Khwaja,et al.  PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways , 2005, Leukemia.

[20]  C. Billottet,et al.  Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation. , 2009, Cancer research.

[21]  P. Finan,et al.  Essential role for the p110δ phosphoinositide 3-kinase in the allergic response , 2004, Nature.

[22]  E. Solary,et al.  Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia , 2005 .

[23]  C. Récher,et al.  mTOR, a new therapeutic target in acute myeloid leukemia. , 2005, Cell cycle.

[24]  Leo Koenderman,et al.  Protein kinase B (c-akt) regulates hematopoietic lineage choice decisions during myelopoiesis. , 2008, Blood.

[25]  David Komander,et al.  Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. , 2003, The Biochemical journal.

[26]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.

[27]  L. Cantley,et al.  PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.

[28]  J. Cheong,et al.  Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable , 2003, Leukemia.

[29]  E. Solary,et al.  Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. , 2005, Blood.

[30]  Yoo Hong Min,et al.  Phosphatase and tensin homologue phosphorylation in the C‐terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome , 2003, British journal of haematology.

[31]  C. Chresta,et al.  Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) , 2009, The Biochemical journal.

[32]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[33]  A. Arcaro,et al.  Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway , 2007, Leukemia.

[34]  Joseph Avruch,et al.  Rheb Binds and Regulates the mTOR Kinase , 2005, Current Biology.

[35]  H. Kuroda,et al.  Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia , 2003, Nature Medicine.

[36]  G. Mayr,et al.  Reduced proliferation of CD34+ cells from patients with acute myeloid leukemia after gene transfer of INPP5D , 2009, Gene Therapy.

[37]  A. Scuto,et al.  Cotreatment with 17-Allylamino-Demethoxygeldanamycin and FLT-3 Kinase Inhibitor PKC412 Is Highly Effective against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3 , 2004, Cancer Research.

[38]  B. Kemp,et al.  Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. , 2008, Cancer research.

[39]  Philippe Broët,et al.  Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. , 2007, Blood.

[40]  M. Weber,et al.  Increased IκB kinase activity is associated with activated NF-κB in acute myeloid blasts , 2002, Leukemia.

[41]  P. Lagadec,et al.  AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells , 2007, Leukemia.

[42]  M. Carroll,et al.  Survival of acute myeloid leukemia cells requires PI3 kinase activation. , 2003, Blood.

[43]  B. Vanhaesebroeck,et al.  Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Newton,et al.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.

[45]  J. McCubrey,et al.  The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion , 2007, Leukemia.

[46]  David A. Williams,et al.  mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization , 2008, Proceedings of the National Academy of Sciences.

[47]  S. Morrison,et al.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.

[48]  Robbie Loewith,et al.  A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.

[49]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[50]  Z. Estrov,et al.  Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. , 2006, Blood.

[51]  Yang Liu,et al.  TSC–mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species , 2008, The Journal of experimental medicine.

[52]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[53]  P. Bolufer,et al.  Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia , 2009, Leukemia.

[54]  F. Storti.  Ferrata Storti Foundation , 2008 .

[55]  I. Hanamura,et al.  Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia , 2003, Leukemia.

[56]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[57]  N. Gray,et al.  FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[58]  Xi C. He,et al.  PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention , 2006, Nature.

[59]  M. Minden,et al.  Blocking the Raf/MEK/ERK Pathway Sensitizes Acute Myelogenous Leukemia Cells to Lovastatin-Induced Apoptosis , 2004, Cancer Research.

[60]  O. Meyuhas,et al.  Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. , 2006, Trends in biochemical sciences.

[61]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[62]  G. Laurent,et al.  Antileukemic activity of rapamycin in acute myeloid leukemia. , 2005, Blood.

[63]  L. Rönnstrand,et al.  The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit. , 2009, Cellular signalling.

[64]  J. Griffin,et al.  Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. , 2008, Blood.

[65]  G. Martinelli,et al.  Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway , 2005, British journal of haematology.

[66]  B. Vanhaesebroeck,et al.  Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[67]  M. Carroll,et al.  mTOR regulates cell survival after etoposide treatment in primary AML cells. , 2005, Blood.

[68]  M. Konopleva,et al.  The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML , 2008, Leukemia.

[69]  F. Khuri,et al.  LKB1 is necessary for Akt-mediated phosphorylation of proapoptotic proteins. , 2008, Cancer research.

[70]  D. Howard,et al.  Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. , 2001, Blood.

[71]  J. Tamburini,et al.  Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110δ mutations , 2006, Leukemia.

[72]  D. Sabatini,et al.  DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival , 2009, Cell.

[73]  K. Shokat,et al.  PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML , 2008, Leukemia.

[74]  J. Dick,et al.  Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity , 2004, Nature Immunology.

[75]  D. Sabatini,et al.  Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. , 2007, Blood.

[76]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[77]  C. Jordan.  The leukemic stem cell. , 2007, Best practice & research. Clinical haematology.

[78]  P. Brousset,et al.  Assessment of somatic mutations in phosphatidylinositol 3‐kinase gene in human lymphoma and acute leukaemia , 2005, British journal of haematology.

[79]  José Luis de la Pompa,et al.  Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN , 1998, Cell.

[80]  J. Graff,et al.  eIF-4E expression and its role in malignancies and metastases , 2004, Oncogene.

[81]  Christian Buske,et al.  A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis , 2008, The Journal of experimental medicine.

[82]  J. Baselga,et al.  NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. , 2008, Cancer research.

[83]  G. Mills,et al.  Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. , 2007, Cancer research.

[84]  J. Myklebust,et al.  Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34(+) hematopoietic progenitor cells. , 2002, Experimental hematology.

[85]  G. Mills,et al.  Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. , 2006, Cancer research.

[86]  D. Sabatini,et al.  An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.

[87]  K. Okkenhaug,et al.  Antigen receptor signalling: a distinctive role for the p110δ isoform of PI3K , 2007, Trends in immunology.

[88]  David E. Williams,et al.  Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. , 2007, Blood.

[89]  J. Tamburini,et al.  Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody , 2010, Haematologica.

[90]  D. Gilliland.  Targeted therapies in myeloid leukemias. , 2004, Annals of hematology.

[91]  J. Gills,et al.  The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt , 2004, Expert opinion on investigational drugs.

[92]  C. Jordan.  Searching for leukemia stem cells--not yet the end of the road? , 2006, Cancer cell.

[93]  정준원,et al.  Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome , 2003 .

[94]  C. Récher,et al.  A critical role for Lyn in acute myeloid leukemia. , 2008, Blood.

[95]  P. Hawkins,et al.  Signalling through Class I PI3Ks in mammalian cells. , 2006, Biochemical Society transactions.

[96]  S. Armstrong,et al.  FoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress , 2007, Cell.

[97]  D. Howard,et al.  Preferential induction of apoptosis for primary human leukemic stem cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[98]  Steven M Kornblau,et al.  Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. , 2004, Blood.

[99]  C. Billottet,et al.  A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. , 2006, Oncogene.

[100]  Jason A. Koutcher,et al.  Identification of a tumour suppressor network opposing nuclear Akt function , 2006, Nature.

[101]  Jiahuai Han,et al.  Phosphatidylinositol Ether Lipid Analogues That Inhibit AKT Also Independently Activate the Stress Kinase, p38α, through MKK3/6-independent and -dependent Mechanisms* , 2007, Journal of Biological Chemistry.

[102]  E. Greer,et al.  FOXO transcription factors at the interface between longevity and tumor suppression , 2005, Oncogene.

[103]  W. Min,et al.  Hsp90–Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis , 2005, Oncogene.

[104]  J. Salles,et al.  A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia , 2006, Oncogene.

[105]  X. Bai,et al.  Rheb Activates mTOR by Antagonizing Its Endogenous Inhibitor, FKBP38 , 2007, Science.

[106]  L. Rönnstrand,et al.  Gab2 Is Involved in Differential Phosphoinositide 3-Kinase Signaling by Two Splice Forms of c-Kit* , 2008, Journal of Biological Chemistry.

[107]  M. Shikami,et al.  Autocrine pathway of angiopoietins-Tie2 system in AML cells: association with phosphatidyl-inositol 3 kinase. , 2004, The hematology journal : the official journal of the European Haematology Association.

[108]  J. McCubrey,et al.  Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. , 2008, Cancer research.

[109]  D. Scadden,et al.  The leukemic stem cell niche: current concepts and therapeutic opportunities. , 2009, Blood.

[110]  C. Lacombe,et al.  Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. , 2003, Blood.

[111]  M. Minden,et al.  Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients. , 2006, Experimental hematology.

[112]  Robbie Loewith,et al.  Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 , 2009, PLoS biology.

[113]  D. Guertin,et al.  Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. , 2006, Developmental cell.

[114]  T. Tsuruo,et al.  Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine) , 2002, Oncogene.

[115]  D. Alessi,et al.  mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). , 2008, The Biochemical journal.

[116]  I. Gout,et al.  The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.

[117]  Daniela Gabriel,et al.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.

[118]  D. Hommes,et al.  Regulation of p110δ PI 3-Kinase Gene Expression , 2009, PloS one.

[119]  J. Tamburini,et al.  Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. , 2009, Blood.